ClinicalTrials.gg

Program

triptorelin

Also written as “Triptorelin embonate 22.5 mg”, “Triptorelin (Decapeptyl®)” and “Decapeptyl® SR 22.5mg”.

Its studies are mostly in Prostatic Neoplasms · Puberty, Precocious · Ovarian Hyperstimulation Syndrome, led by 5 companies.

Furthest: phase 4, since Aug 23, 201220 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ipsen130 open or runningphase 4since Aug 23, 2012Dec 21, 2006none ahead
Debiopharm30 open or runningphase 3since Sep 11, 2008Sep 11, 2008none ahead
Foresee Pharmaceuticals20 open or runningphase 3since Jan 22, 2025Jan 22, 2025none ahead
AbbVie10 open or runningphase 4since Jul 9, 2010Jul 9, 2010none ahead
Pharmatech10 open or runningphase 4since May 8, 2012May 8, 2012none ahead

Also a collaborator on its studies: qps-holdings-llc and quintiles-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Dec 21, 2006.

  1. Nov 24, 2009Phase 3 study in Prostatic NeoplasmsIpsen · NCT01020448 · 339 enrolled · Belgium, Denmark, France and more
  2. Jul 9, 2010AbbVie's first study: phase 4 study in Prostatic NeoplasmsNew to AbbVieAbbVie · NCT01161563 · 118 enrolled · United States
  3. Dec 8, 2010Phase 2 study in Prostatic NeoplasmsIpsen · NCT01257425 · 109 enrolled · Germany
  4. Jun 14, 2011Phase 2 study in Prostatic NeoplasmsIpsen · NCT01374087 · 32 enrolled · Spain
  5. Nov 7, 2011Phase 3 study in Puberty, PrecociousDebiopharm · NCT01467882 · 44 enrolled · United States, Chile, Mexico
  6. May 8, 2012Pharmatech's first study: phase 4 study in Prostatic NeoplasmsNew to PharmatechPharmatech · NCT02749825 · 41 enrolled · United States
  7. Jul 31, 2012Phase 3 study in Prostatic NeoplasmsDebiopharm · NCT01656161 · 120 enrolled · South Africa
  8. Aug 23, 2012Phase 4 study in Prostatic NeoplasmsIpsen · NCT01673984 · 27 enrolled · United Kingdom
  9. Oct 24, 2012Phase 3 study in Prostatic NeoplasmsIpsen · NCT01715129 · 126 enrolled · Bulgaria, France, Latvia and more
  10. Dec 17, 2012Phase 4 study in Prostatic NeoplasmsIpsen · NCT01753297 · 226 enrolled · China, Russian Federation
  11. Jan 29, 2021Phase 3 study in Puberty, PrecociousIpsen · NCT04736602 · 32 enrolled · China
  12. Aug 9, 2021Phase 3 study in Puberty, PrecociousIpsen · NCT05029622 · 66 enrolled · China
  13. Jun 17, 2022Phase 3 study in Prostatic NeoplasmsIpsen · NCT05458856 · 147 enrolled · Belgium, Czechia, France and more
  14. Jan 22, 2025Foresee Pharmaceuticals's first studies: 2 phase 3 studies in Prostatic NeoplasmsNew to Foresee PharmaceuticalsForesee Pharmaceuticals · NCT06795191, NCT06795178

TargetBeta

GNRH1 →GNRHR →read by rule
“A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH)”NCIt, by rule
“Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
GoserelinruleAstraZenecaphase 414

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06795191Prostatic Neoplasms3WithdrawnForesee PharmaceuticalsNov 30, 20270
NCT06795178Prostatic Neoplasms3WithdrawnForesee PharmaceuticalsDec 31, 20270
NCT05458856Prostatic Neoplasms · Belgium, Czechia, France and more3CompletedIpsenJul 8, 2024147
NCT05029622Puberty, Precocious · China3CompletedIpsenAug 21, 202266
NCT04736602Puberty, Precocious · China3CompletedIpsenFeb 9, 202232
NCT01753297Prostatic Neoplasms · China, Russian Federation4CompletedIpsenSep 9, 2019226
NCT01715129Prostatic Neoplasms · Bulgaria, France, Latvia and more3CompletedIpsenOct 2013126
NCT01673984Prostatic Neoplasms · United Kingdom4TerminatedIpsenFeb 201427
NCT01656161Prostatic Neoplasms · South Africa3CompletedDebiopharmAug 2013120
NCT02749825Prostatic Neoplasms · United States4TerminatedPharmatechMay 200641
NCT01467882Puberty, Precocious · United States, Chile, Mexico3CompletedDebiopharmAug 201344
NCT01374087Prostatic Neoplasms · Spain2TerminatedIpsenDec 201432
NCT01257425Prostatic Neoplasms · Germany2CompletedIpsenFeb 2012109
NCT01161563Prostatic Neoplasms · United States4CompletedAbbVieApr 2011118
NCT01020448Prostatic Neoplasms · Belgium, Denmark, France and more3CompletedIpsenNov 2011339
NCT00909844Puberty, Precocious · France3CompletedIpsenApr 201535
NCT00751790Prostatic Neoplasms · South Africa3CompletedDebiopharmAug 2007120
NCT00564850Puberty, Precocious · France3CompletedIpsenOct 201037
NCT00444639Prostatic Neoplasms · Netherlands2TerminatedIpsenFeb 200825
NCT00415246Prostatic Neoplasms · Belgium, France, Latvia and more3TerminatedIpsen100

How it is read

Names in the registry

  • “Triptorelin embonate 22.5 mg”, 2 entries
  • “Triptorelin (Decapeptyl®)”, 2 entries
  • “Decapeptyl® SR 22.5mg”, 1 entry
  • “Triptorelin Mesylate”, 1 entry
  • “FP-014”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.